GSK malaria vaccine trial halted in Gabon
This article was originally published in Scrip
Executive Summary
Gabon has decided to put on hold the start date of a Phase III trial of GlaxoSmithKline's malaria vaccine (RTS,S, AS01/AS02), the most advanced vaccine for the condition to date, which was expected to begin this week in children under two years of age. A roll-out of the trial across seven African countries at 11 sites is expected from mid-April.